Abstract
Summary
The Europe non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 8.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Europe Non-Hodgkin lymphoma diagnostics market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Rest of Europe) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Europe non-Hodgkin lymphoma diagnostics market are:
• Increased growth in the prevalence of Non-Hodgkin Lymphoma
• Advancement in artificial intelligence in the diagnosis of Non-Hodgkin Lymphoma
Market Players:
Some of the major players operating in the Europe non-Hodgkin lymphoma diagnostics market are:
• CANON MEDICAL SYSTEMS CORPORATION
• Koninklijke Philips N.V.
• Siemens Healthcare GmbH
• Danaher.
• Bio-Rad Laboratories, Inc.
• General Electric Company
• Sysmex Corporation
• Grail
• F. Hoffmann-La Roche
• Neusoft Corporation
• Agilent Technologies, Inc.
• NeoGenomics Laboratories
• Hologic, Inc
• Integrated DNA Technologies, Inc.
• CENTOGENE N.V.
• Merit Medical Systems
• Invitae Corporation
• PerkinElmer Inc.
• QIAGEN
• GeneDx, LLC
Table of Contents
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 84
1.4 LIMITATIONS 86
1.5 MARKETS COVERED 87
2 MARKET SEGMENTATION 90
2.1 MARKETS COVERED 90
2.2 GEOGRAPHICAL SCOPE 91
2.3 YEARS CONSIDERED FOR THE STUDY 92
2.4 CURRENCY AND PRICING 92
2.5 DBMR TRIPOD DATA VALIDATION MODEL 93
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE LIFELINE CURVE 96
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.9 DBMR MARKET POSITION GRID 98
2.10 MARKET APPLICATION COVERAGE GRID 99
2.11 VENDOR SHARE ANALYSIS 100
2.12 SECONDARY SOURCES 101
2.13 ASSUMPTIONS 101
3 EXECUTIVE SUMMARY 102
4 PREMIUM INSIGHTS 105
4.1 PESTEL ANALYSIS 106
4.2 PORTER'S 5 FORCES 107
5 INDUSTRY INSIGHTS 108
6 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 109
7 MARKET OVERVIEW 111
7.1 DRIVERS 113
7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 113
7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 113
7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 113
7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 114
7.2 RESTRAINTS 114
7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 114
7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 115
7.3 OPPORTUNITIES 116
7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 116
7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 116
7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 116
7.4 CHALLENGES 117
7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 117
7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 117
7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 118
8 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 119
8.1 OVERVIEW 120
8.2 IMAGING 123
8.2.1 COMPUTED TOMOGRAPHY (CT) 124
8.2.2 CHEST X-RAY 124
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 124
8.2.4 ULTRASOUND 124
8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 124
8.3 BIOPSY 124
8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 125
8.3.2 CORE NEEDLE BIOPSY 125
8.4 IMMUNOHISTOCHEMISTRY 125
8.5 BIOMARKER TEST 126
8.5.1 BETA 2-M 127
8.5.2 LDH 127
8.5.3 CA-125 127
8.5.4 TP53 127
8.5.5 NPM1 128
8.5.6 OTHERS 128
8.6 GENETIC TEST 128
8.7 CYTOGENETICS 128
8.8 LUMBAR PUNCTURE (SPINAL TAP) 129
8.9 BLOOD TEST 130
8.10 CYTOCHEMISTRY 130
8.11 OTHERS 131
9 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 132
9.1 OVERVIEW 133
9.2 AGGRESSIVE LYMPHOMAS 135
9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 136
9.2.1.1 INSTRUMENT BASED PRODUCTS 137
9.2.1.2 PLATFORM BASED PRODUCTS 137
9.2.1.3 KITS AND REAGENTS 137
9.2.1.4 OTHER CONSUMABLES 137
9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 137
9.2.2.1 INSTRUMENT BASED PRODUCTS 138
9.2.2.2 PLATFORM BASED PRODUCTS 138
9.2.2.3 KITS AND REAGENTS 138
9.2.2.4 OTHER CONSUMABLES 138
9.2.3 MANTLE CELL LYMPHOMA 138
9.2.3.1 INSTRUMENT BASED PRODUCTS 139
9.2.3.2 PLATFORM BASED PRODUCTS 139
9.2.3.3 KITS AND REAGENTS 139
9.2.3.4 OTHER CONSUMABLES 139
9.2.4 PERIPHERAL T-CELL LYMPHOMA 139
9.2.4.1 INSTRUMENT BASED PRODUCTS 140
9.2.4.2 PLATFORM BASED PRODUCTS 140
9.2.4.3 KITS AND REAGENTS 140
9.2.4.4 OTHER CONSUMABLES 140
9.2.5 LYMPHOBLASTIC LYMPHOMA 140
9.2.5.1 INSTRUMENT BASED PRODUCTS 141
9.2.5.2 PLATFORM BASED PRODUCTS 141
9.2.5.3 KITS AND REAGENTS 141
9.2.5.4 OTHER CONSUMABLES 141
9.2.6 BURKITT LYMPHOMA 141
9.2.6.1 INSTRUMENT BASED PRODUCTS 142
9.2.6.2 PLATFORM BASED PRODUCTS 142
9.2.6.3 KITS AND REAGENTS 142
9.2.6.4 OTHER CONSUMABLES 142
9.3 INDOLENT LYMPHOMAS 142
9.3.1 FOLLICULAR LYMPHOMA 143
9.3.1.1 INSTRUMENT BASED PRODUCTS 144
9.3.1.2 PLATFORM BASED PRODUCTS 144
9.3.1.3 KITS AND REAGENTS 144
9.3.1.4 OTHER CONSUMABLES 144
9.3.2 CUTANEOUS T-CELL LYMPHOMA 144
9.3.2.1 INSTRUMENT BASED PRODUCTS 145
9.3.2.2 PLATFORM BASED PRODUCTS 145
9.3.2.3 KITS AND REAGENTS 145
9.3.2.4 OTHER CONSUMABLES 145
9.3.3 MARGINAL ZONE B CELL LYMPHOMA 145
9.3.3.1 INSTRUMENT BASED PRODUCTS 146
9.3.3.2 PLATFORM BASED PRODUCTS 146
9.3.3.3 KITS AND REAGENTS 146
9.3.3.4 OTHER CONSUMABLES 146
9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 146
9.3.4.1 INSTRUMENT BASED PRODUCTS 147
9.3.4.2 PLATFORM BASED PRODUCTS 147
9.3.4.3 KITS AND REAGENTS 147
9.3.4.4 OTHER CONSUMABLES 147
9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 147
9.3.5.1 INSTRUMENT BASED PRODUCTS 148
9.3.5.2 PLATFORM BASED PRODUCTS 148
9.3.5.3 KITS AND REAGENTS 148
9.3.5.4 OTHER CONSUMABLES 148
10 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 149
10.1 OVERVIEW 150
10.2 SCREENING 152
10.2.1 INSTRUMENT BASED PRODUCTS 153
10.2.2 PLATFORM BASED PRODUCTS 153
10.2.3 KITS AND REAGENTS 154
10.2.4 OTHER CONSUMABLES 154
10.3 DIAGNOSTIC AND PREDICTIVE 154
10.3.1 INSTRUMENT BASED PRODUCTS 155
10.3.2 PLATFORM BASED PRODUCTS 155
10.3.3 KITS AND REAGENTS 155
10.3.4 OTHER CONSUMABLES 155
10.4 PROGNOSTIC 155
10.4.1 INSTRUMENT BASED PRODUCTS 156
10.4.2 PLATFORM BASED PRODUCTS 156
10.4.3 KITS AND REAGENTS 156
10.4.4 OTHER CONSUMABLES 157
10.5 RESEARCH 157
10.5.1 INSTRUMENT BASED PRODUCTS 158
10.5.2 PLATFORM BASED PRODUCTS 158
10.5.3 KITS AND REAGENTS 158
10.5.4 OTHER CONSUMABLES 158
11 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 159
11.1 OVERVIEW 160
11.2 STAGE IV 162
11.3 STAGE I 163
11.4 STAGE III 164
11.5 STAGE II 165
11.6 STAGE 0 166
12 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 167
12.1 OVERVIEW 168
12.2 FLUORESCENT IN SITU HYBRIDIZATION 170
12.3 NEXT GENERATION SEQUENCING 171
12.4 FLUORIMMUNOASSAY 172
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 173
12.6 IMMUNOHISTOLOCHEMICAL 173
12.7 OTHER 174
13 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 175
13.1 OVERVIEW 176
13.2 INSTRUMENT BASED PRODUCTS 178
13.2.1 IMAGING 179
13.2.2 BIOPSY 179
13.3 PLATFORM BASED PRODUCTS 180
13.3.1 NEXT-GENERATION SEQUENCING 181
13.3.2 MICROARRAYS 181
13.3.3 PCR 181
13.3.4 OTHERS 181
13.4 KITS AND REAGENTS 181
13.4.1 NON-HODGKIN LYMPHOMA PANELS 182
13.4.2 IMMUNOHISTOCHEMISTRY STAINS 182
13.4.3 OTHERS 182
13.5 OTHER CONSUMABLES 183
14 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 184
14.1 OVERVIEW 185
14.2 HOSPITALS 187
14.3 DIAGNOSTIC CENTERS 188
14.4 CANCER RESEARCH CENTERS 189
14.5 ACADEMIC INSTITUTES 190
14.6 AMBULATORY SURGICAL CENTERS 190
14.7 OTHERS 191
15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 192
15.1 OVERVIEW 193
15.2 DIRECT TENDER 195
15.3 RETAIL SALES 196
15.4 OTHERS 197
16 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 198
16.1 EUROPE 199
16.1.1 GERMANY 218
16.1.2 UNITED KINGDOM 230
16.1.3 FRANCE 242
16.1.4 ITALY 254
16.1.5 SPAIN 266
16.1.6 RUSSIA 278
16.1.7 NETHERLANDS 290
16.1.8 SWITZERLAND 302
16.1.9 BELGIUM 314
16.1.10 TURKEY 326
16.1.11 REST OF EUROPE 338
17 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 339
17.1 COMPANY SHARE ANALYSIS: EUROPE 339
18 SWOT ANALYSIS 340
19 EUROPE NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 341
19.1 CANON MEDICAL SYSTEMS CORPORATION 341
19.1.1 COMPANY SNAPSHOT 341
19.1.2 REVENUE ANALYSIS 341
19.1.3 COMPANY SHARE ANALYSIS 342
19.1.4 PRODUCT PORTFOLIO 342
19.1.5 RECENT DEVELOPMENT 342
19.2 KONINKLIJKE PHILIPS N.V 343
19.2.1 COMPANY SNAPSHOT 343
19.2.2 REVENUE ANALYSIS 343
19.2.3 COMPANY SHARE ANALYSIS 344
19.2.4 PRODUCT PORTFOLIO 344
19.2.5 RECENT DEVELOPMENTS 344
19.3 SIEMENS HEALTHCARE GMBH 345
19.3.1 COMPANY SNAPSHOT 345
19.3.2 REVENUE ANALYSIS 345
19.3.3 COMPANY SHARE ANALYSIS 346
19.3.4 PRODUCT PORTFOLIO 346
19.3.5 RECENT DEVELOPMENT 347
19.4 DANAHER 348
19.4.1 COMPANY SNAPSHOT 348
19.4.2 REVENUE ANALYSIS 348
19.4.3 COMPANY SHARE ANALYSIS 349
19.4.4 PRODUCT PORTFOLIO 349
19.4.5 RECENT DEVELOPMENTS 350
19.5 BIO-RAD LABORATORIES, INC 351
19.5.1 COMPANY SNAPSHOT 351
19.5.2 REVENUE ANALYSIS 351
19.5.3 COMPANY SHARE ANALYSIS 352
19.5.4 PRODUCT PORTFOLIO 352
19.5.5 RECENT DEVELOPMENT 352
19.6 AGILENT TECHNOLOGIES, INC 353
19.6.1 COMPANY PROFILE 353
19.6.2 REVENUE ANALYSIS 353
19.6.3 PRODUCT PORTFOLIO 354
19.6.4 RECENT DEVELOPMENT 354
19.7 CENTOGENE N.V 355
19.7.1 COMPANY SNAPSHOT 355
19.7.2 PRODUCT PORTFOLIO 355
19.7.3 RECENT DEVELOPMENT 355
19.8 F. HOFFMANN- LA ROCHE LTD 356
19.8.1 COMPANY SNAPSHOT 356
19.8.2 REVENUE ANALYSIS 356
19.8.3 PRODUCT PORTFOLIO 357
19.8.4 RECENT DEVELOPMENTS 357
19.9 GENERAL ELECTRIC COMPANY 358
19.9.1 COMPANY SNAPSHOT 358
19.9.2 REVENUE ANALYSIS 358
19.9.3 PRODUCT PORTFOLIO 359
19.9.4 RECENT DEVELOPMENTS 359
19.10 GENEDX, LLC 360
19.10.1 COMPANY SNAPSHOT 360
19.10.2 PRODUCT PORTFOLIO 360
19.10.3 RECENT DEVELOPMENT 360
19.11 GRAIL 361
19.11.1 COMPANY PROFILE 361
19.11.2 PRODUCT PORTFOLIO 361
19.11.3 RECENT DEVELOPMENT 361
19.12 HOLOGIC INC 362
19.12.1 COMPANY SNAPSHOT 362
19.12.2 REVENUE ANALYSIS 362
19.12.3 PRODUCT PORTFOLIO 363
19.12.4 RECENT DEVELOPMENT 363
19.13 INVITAE CORPORATION 364
19.13.1 COMPANY PROFILE 364
19.13.2 REVENUE ANALYSIS 364
19.13.3 PRODUCT PORTFOLIO 365
19.13.4 RECENT DEVELOPMENT 365
19.14 NEUSOFT CORPORATION 366
19.14.1 COMPANY SNAPSHOT 366
19.14.2 REVENUE ANALYSIS 366
19.14.3 PRODUCT PORTFOLIO 367
19.14.4 RECENT DEVELOPMENT 367
19.15 NEOGENOMICS LABORATORIES 368
19.15.1 COMPANY SNAPSHOT 368
19.15.2 REVENUE ANALYSIS 368
19.15.3 PRODUCT PORTFOLIO 369
19.15.4 RECENT DEVELOPMENTS 369
19.16 PERKINELMER INC 370
19.16.1 COMPANY PROFILE 370
19.16.2 REVENUE ANALYSIS 370
19.16.3 PRODUCT PORTFOLIO 371
19.16.4 RECENT DEVELOPMENT 371
19.17 QIAGEN 372
19.17.1 COMPANY SNAPSHOT 372
19.17.2 REVENUE ANALYSIS 372
19.17.3 PRODUCT PORTFOLIO 373
19.17.4 RECENT DEVELOPMENT 373
19.18 SYSMEX CORPORATION 374
19.18.1 COMPANY SNAPSHOT 374
19.18.2 REVENUE ANALYSIS 374
19.18.3 PRODUCT PORTFOLIO 375
19.18.4 RECENT DEVELOPMENTS 375
20 QUESTIONNAIRE 376
21 RELATED REPORTS 380